secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0001437749-24-037061
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA provides roadmap for accelerated approval of Clene's CNM-Au8 in ALS via additional NfL biomarker data
--------------------------------------------------------------------------------

- FDA recommends leveraging additional NfL data from three Expanded Access Protocols and HEALEY trial to support accelerated approval; follow-up meeting early 2025.
- Additional NfL biomarker analyses planned to complete Q2 2025; NDA submission targeted mid-2025.
- Confirmatory Phase 3 RESTORE-ALS trial to start enrollment before NDA submission, evaluating survival benefit.
- Key survival data from November meeting: 78% risk reduction in time to death at Month 12 (HR=0.224, p=0.042).
- Over 700 patient-years of CNM-Au8 use with no significant safety concerns; no SAEs related to treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774924037061/0001437749-24-037061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774924037061/clnn20241209_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-037061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer